Digest Network Come funziona
Network
/
Società
St
Non verificato

Stoke Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

57 comunicati stampa

Guarda tutti i comunicati
30/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Sanità
Farmaceutica
Salute
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/04/2026
Mercato azionario
Finanza
Salute
Biotecnologia
Scienza
Farmaceutica
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
08/04/2026
Eventi
Web e Social Network
Salute
Biotecnologia
Scienza
Medicina - Varie
Farmaceutica
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/04/2026
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/03/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato azionario
Finanza
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/03/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/02/2026
Eventi
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
18/02/2026
Mercato azionario
Finanza
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/02/2026
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Ottica
Industria
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/02/2026
Biotecnologia
Salute
Web e Social Network
Eventi
Fiere
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Fonte
Stoke Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0